Control of ASPP2/(53BP2L) protein levels by proteasomal degradation modulates p53 apoptotic function (Q40386976)

20 September 2017

title

Control of ASPP2/(53BP2L) protein levels by proteasomal degradation modulates p53 apoptotic function (English)

1 reference

20 September 2017

0 references

Zhiyi Zhu

1

1 reference

20 September 2017

Jason Ramos

2

1 reference

20 September 2017

Kerstin Kampa

3

1 reference

20 September 2017

Shanthi Adimoolam

4

1 reference

20 September 2017

Mint Sirisawad

5

1 reference

20 September 2017

Zhiyong Yu

6

1 reference

20 September 2017

Dexi Chen

7

1 reference

20 September 2017

Louie Naumovski

8

1 reference

20 September 2017

Charles D Lopez

9

1 reference

20 September 2017

language of work or name

English

0 references

publication date

9 August 2005

1 reference

Journal of Biological Chemistry

20 September 2017

published in

1 reference

20 September 2017

volume

280

1 reference

20 September 2017

issue

41

1 reference

20 September 2017

page(s)

34473-34480

1 reference

Live or let die: the cell's response to p53

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M503736200

Apoptosis: a link between cancer genetics and chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M503736200

Two cellular proteins that bind to wild-type but not mutant p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M503736200

ASPP proteins specifically stimulate the apoptotic function of p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M503736200

Expression of 53BP2 and ASPP2 proteins from TP53BP2 gene by alternative splicing

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M503736200

Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M503736200

Stimulation of p53-mediated transcriptional activation by the p53-binding proteins, 53BP1 and 53BP2

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M503736200

p53-interacting protein 53BP2 inhibits clonogenic survival and sensitizes cells to doxorubicin but not paclitaxel-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M503736200

Proapoptotic p53-interacting protein 53BP2 is induced by UV irradiation but suppressed by p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M503736200

ASPP1 and ASPP2: common activators of p53 family members

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M503736200

NF-kappaB subunit p65 binds to 53BP2 and inhibits cell death induced by 53BP2

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M503736200

Apoptosis-stimulating protein of p53-2 (ASPP2/53BP2L) is an E2F target gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M503736200

Proteasome inhibition as a novel therapeutic target in human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M503736200

The development of proteasome inhibitors as anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M503736200

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M503736200

Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M503736200

Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M503736200

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M503736200

Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M503736200

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M503736200

Chk2 activates E2F-1 in response to DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M503736200

Requirement for p53 and p21 to sustain G2 arrest after DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M503736200

Ubiquitin-dependent c-Jun degradation in vivo is mediated by the delta domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M503736200

ASPP1 and ASPP2 are new transcriptional targets of E2F

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M503736200

Novel link between E2F and p53: proapoptotic cofactors of p53 are transcriptionally upregulated by E2F.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M503736200

Differential regulation of E2F1 apoptotic target genes in response to DNA damage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M503736200

Aberrant overexpression of 53BP2 mRNA in lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M503736200

The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M503736200

RETRACTED: Regulation of p53: intricate loops and delicate balances

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M503736200

21 January 2018

Identifiers

DOI

10.1074/JBC.M503736200

1 reference

20 September 2017

1 reference